The standout for CNO heading into today's Q1 2026 results is a broad, coordinated wave of insider selling — every C-suite executive sold shares on the same day, at the same price, just five weeks before the print.

The standout for CNO heading into today's Q1 2026 results is a broad, coordinated wave of insider selling — every C-suite executive sold shares on the same day, at the same price, just five weeks before the print.

On March 25, every named executive at CNO Financial Group sold stock, from CEO Gary Bhojwani down to the Chief Accounting Officer. Bhojwani led the cluster, offloading 45,746 shares at $40.61 apiece for roughly $1.86 million. The CFO, CIO, COO, CMO, and HR Director all sold on the same date. Across the 90-day window, insiders have been net sellers of approximately 378,410 shares, with total net sales value reaching ~$16 million. That breadth — ten executives moving in lockstep — is the defining feature of the pre-earnings setup.

The analyst community presents a mixed but largely constructive picture. Keefe, Bruyette & Woods reinstated coverage in late March with a Market Perform and a $46 target, essentially matching where the stock trades today at $44.45. Evercore ISI maintained its Underperform in February, lifting its target only marginally to $43. On the bullish side, Piper Sandler holds an Overweight with a $50 target, and Jefferies upgraded to Buy late last year with a $47 target. The consensus mean sits at $46 — modest implied upside — suggesting the Street sees fair value roughly in line with the current price rather than a compelling re-rating opportunity. The stock itself has recovered strongly, up 10.6% over the past month despite a fractional pullback on Wednesday.